Colorectal Cancer Screening Tests | CMS Coverage Update

Summary: The Centers for Medicare & Medicaid Services modified its colorectal cancer screening tests coverage policy, effective May 15, 2026. Here's what billing teams need to know before that date.

CMS colorectal cancer screening coverage has been a moving target for years. Each update shifts which tests qualify, what age thresholds apply, and how frequently Medicare will reimburse. This modification — effective May 15, 2026 — is no exception. The policy does not carry a numbered policy code in this version, but it governs a high-volume category across gastroenterology, primary care, and preventive medicine billing. If your practice bills colorectal cancer screening to Medicare, this change affects your workflow now.

Quick-Reference Table

CMS Colorectal Cancer Screening Coverage Criteria and Medical Necessity Requirements 2026

CMS colorectal cancer screening coverage policy sits under the Medicare preventive benefit. That framing matters for billing. Preventive services carry different cost-sharing rules, different modifier requirements, and different rules around what happens when a screening turns into a diagnostic procedure mid-encounter.

The core medical necessity standard for Medicare-covered colorectal screening is age and risk. Medicare covers screening for beneficiaries at average risk starting at age 45. That age threshold dropped from 50 to 45 in recent years, aligning with updated U.S. Preventive Services Task Force (USPSTF) guidelines. If your charge capture still defaults to 50 as the eligibility floor, fix it now — before May 15, 2026.

CMS covers several distinct test types under this benefit. Each carries its own frequency limitation and medical necessity criteria. Fecal occult blood tests (FOBT) are covered annually. Flexible sigmoidoscopy is covered every four years for average-risk patients, or every 10 years following a negative colonoscopy. Colonoscopy for average-risk patients is covered every 10 years. High-risk patients — those with a family history of colorectal cancer or adenomatous polyps, or personal history of adenomas — qualify for colonoscopy every two years.

Stool-based DNA tests (like Cologuard) are covered every three years for average-risk Medicare beneficiaries between ages 45 and 85. This frequency limitation is a common source of claim denial. If a patient had a stool DNA test less than three years ago, a new claim will not pass Medicare's claim history check.

Prior authorization is not currently required for most colorectal screening services under Medicare fee-for-service. However, if your patients are in Medicare Advantage plans, prior authorization requirements vary by plan. Do not assume fee-for-service rules carry over. Call the plan before the procedure when there's any doubt.

The medical necessity documentation burden for screening colonoscopy escalates when a polyp is found and removed during the same session. At that point, the encounter converts from screening to diagnostic for coding purposes. You need to apply the right modifier and correct the diagnosis coding. Failing to do this is one of the most consistent sources of underpayment in GI billing.

CMS Colorectal Cancer Screening Exclusions and Non-Covered Indications

CMS does not cover colorectal screening outside defined frequency limits. A colonoscopy performed less than 10 years after a prior negative screening colonoscopy for an average-risk patient does not meet medical necessity criteria. Billing it as screening will result in a claim denial.

Screening services billed with diagnosis codes that indicate active symptoms are a red flag. If a patient presents with rectal bleeding or a change in bowel habits, that's a diagnostic workup — not a screening. Billing a diagnostic colonoscopy with screening modifiers and benefit codes is a compliance problem, not just a reimbursement problem. Your compliance officer needs to be part of any process that involves converting diagnostic encounters to screening billing.

CMS also does not cover colorectal cancer screening for beneficiaries under age 45 under this benefit. Some Medicare Advantage plans may follow different rules, but traditional Medicare will deny claims for patients below the age threshold.

Experimental or investigational colorectal screening technologies — tests not yet reviewed and approved by CMS or the USPSTF — are not covered under this benefit. If a new stool-based biomarker test comes to market and your physicians want to offer it, check for an NCD or LCD before billing Medicare.

Coverage Indications at a Glance

CMS Colorectal Cancer Screening Billing Guidelines and Action Items 2026

This is where the real work happens. The policy modification effective May 15, 2026 is your trigger to audit the full workflow — not just update a code list.

CPT, HCPCS, and ICD-10 Codes for Colorectal Cancer Screening Under CMS Policy

The policy document for this modification does not list specific CPT, HCPCS, or ICD-10 codes. That's worth noting — CMS policy documents for screening benefits often reference HCPCS G-codes rather than CPT codes, and the applicable codes can be found in the Medicare Claims Processing Manual and the annual HCPCS updates.

Commonly Billed Codes for CMS Colorectal Cancer Screening (Based on Current Medicare Billing Guidelines)

These codes reflect the standard colorectal cancer screening billing framework under Medicare. Confirm each against the May 15, 2026 effective policy version and your Medicare Administrative Contractor's guidance.

Important: Confirm G0306 coverage and effective dates with your MAC. Stool-based biomarker coding has been an area of active CMS updates. Your Medicare Administrative Contractor may have a local coverage determination that affects reimbursement for specific stool DNA products.

Key ICD-10-CM Diagnosis Codes

Again — the policy document for this modification does not enumerate codes directly. Cross-reference these against your MAC's LCD and the CMS claims processing guidance before the May 15, 2026 effective date.